News Releases
View all Historical Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 19, 2025
50 of 80 patients enrolled in FLASH2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the...
-
Nov 7, 2025
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Oct 14, 2025
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a...
-
Oct 7, 2025
FLASH2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or...
-
Sep 30, 2025
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the...